Geeta S. Vemuri
Fondateur chez Agent Capital LLC
Profil
Geeta S.
Vemuri is the founder of Agent Capital LLC, which was founded in 2017.
She currently holds the position of Director at Southeast BIO, Director at Immunitas Therapeutics, Inc., Director at Carbon Biosciences, Inc., and Investment Committee Member at Pathway To Cures.
She also currently holds the position of Director at Illinois Biotechnology Industry Organization since 2014.
Dr. Vemuri's education includes an MBA from Indian Institute of Science, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from Central University of Haryana.
Postes actifs de Geeta S. Vemuri
| Sociétés | Poste | Début |
|---|---|---|
| Southeast BIO | Directeur/Membre du Conseil | - |
Illinois Biotechnology Industry Organization
 Illinois Biotechnology Industry Organization Miscellaneous Commercial ServicesCommercial Services Illinois Biotechnology Industry Organization, also known as ibio, is a state trade association representing the life sciences industry in Illinois. The non-profit company is based in Chicago, IL. The organization's mission is to promote, connect, and engage the life sciences community to drive discovery, transform lives through groundbreaking research, and grow the economy. The company's membership ranges from corporations to startup companies in the biopharma, medical device, and nutrition industries. The Illinois life sciences industry is recognized as a national leader, and ibio's members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed therapeutics and products to transform patients' lives. | Directeur/Membre du Conseil | 01/12/2014 |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Fondateur | 01/01/2017 |
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Directeur/Membre du Conseil | - |
Pathway To Cures
 Pathway To Cures Investment ManagersFinance Pathway To Cures (Pathway To Cures) is a venture capital firm founded in 2022. The firm is headquartered in New York. | Membre du Comité d'Investissement | 27/02/2023 |
Anciens postes connus de Geeta S. Vemuri
| Sociétés | Poste | Fin |
|---|---|---|
Arginetix, Inc.
 Arginetix, Inc. Pharmaceuticals: MajorHealth Technology Arginetix, Inc. develops and manufactures biopharmaceutical products. It develops and commercializes therapeutic small molecule inhibitors of arginase. The company's products are used to produce ornithine which increases polyamine, stimulating cell division, contributing to hyperplasia and fibrosis. Arginetix was founded by David Christianson, Gary Lessing, and Dan Berkowitz in 2007 and is headquartered in Lutherville, MD. | Directeur/Membre du Conseil | 06/12/2012 |
Immune Control, Inc.
 Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Directeur/Membre du Conseil | 06/12/2012 |
Argolyn Bioscience, Inc.
 Argolyn Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Argolyn Bioscience, Inc. discovers and develops therapeutic products. It uses amino acid analog substitution technology to enable discovery of novel drug candidates. The firm's products pipeline include library construction, lead identification, and preclinical & clinical development. The company was founded by Thomas A. Dix in May 2002 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | 26/11/2009 |
| ░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Geeta S. Vemuri
| Indian Institute of Science | Masters Business Admin |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Central University of Haryana | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TENGION, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 28 |
|---|---|
Citigroup Global Markets, Inc. (Broker)
 Citigroup Global Markets, Inc. (Broker) Investment Banks/BrokersFinance Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis. | Finance |
Citigroup Global Markets Holdings, Inc.
 Citigroup Global Markets Holdings, Inc. Investment Banks/BrokersFinance Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY. | Finance |
Argolyn Bioscience, Inc.
Argolyn Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Argolyn Bioscience, Inc. discovers and develops therapeutic products. It uses amino acid analog substitution technology to enable discovery of novel drug candidates. The firm's products pipeline include library construction, lead identification, and preclinical & clinical development. The company was founded by Thomas A. Dix in May 2002 and is headquartered in Durham, NC. | Health Technology |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
NuPathe, Inc.
 NuPathe, Inc. Medical SpecialtiesHealth Technology NuPathe, Inc. develops pharmaceutical and therapeutic products. It focuses on the development and commercialization of branded therapeutics for diseases of central nervous system, including neurological and psychiatric disorders. The company was founded by Terri B. Sebree and Jane Holmes Hollingsworth in 2005 and is headquartered in Malvern, PA. | Health Technology |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
Arginetix, Inc.
Arginetix, Inc. Pharmaceuticals: MajorHealth Technology Arginetix, Inc. develops and manufactures biopharmaceutical products. It develops and commercializes therapeutic small molecule inhibitors of arginase. The company's products are used to produce ornithine which increases polyamine, stimulating cell division, contributing to hyperplasia and fibrosis. Arginetix was founded by David Christianson, Gary Lessing, and Dan Berkowitz in 2007 and is headquartered in Lutherville, MD. | Health Technology |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Toucan Capital Corp.
 Toucan Capital Corp. Investment ManagersFinance Toucan Capital Corp (Toucan Capital) is a private equity firm founded in 1997 by Linda F. Powers and Robert F. Hemphill. The firm is headquartered in Bethesda, Maryland. | Finance |
| Smith Barney Asset Management | Finance |
| First Union Securities | Finance |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Quaker Partners Management LP
 Quaker Partners Management LP Investment ManagersFinance Quaker Partners Management LP (Quaker Partners Mgmt) is a venture capital subsidiary of Independence Capital Partners Inc founded in 2002 by Ira Mark Lubert and Paul Sherrill Neff. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
The Wistar Institute
 The Wistar Institute BiotechnologyHealth Technology The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA | Health Technology |
| Southeast BIO | |
Illinois Biotechnology Industry Organization
Illinois Biotechnology Industry Organization Miscellaneous Commercial ServicesCommercial Services Illinois Biotechnology Industry Organization, also known as ibio, is a state trade association representing the life sciences industry in Illinois. The non-profit company is based in Chicago, IL. The organization's mission is to promote, connect, and engage the life sciences community to drive discovery, transform lives through groundbreaking research, and grow the economy. The company's membership ranges from corporations to startup companies in the biopharma, medical device, and nutrition industries. The Illinois life sciences industry is recognized as a national leader, and ibio's members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed therapeutics and products to transform patients' lives. | Commercial Services |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Corridor Pharmaceuticals, Inc.
 Corridor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corridor Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. The company was founded on February 1, 2008 and is headquartered in Lutherville, MD | Health Technology |
Baxter Ventures
 Baxter Ventures Investment ManagersFinance Baxter Ventures (Baxter Ventures) is a venture capital firm subsidiary of Baxter International, Inc. founded in 2011. The firm is headquartered in Deerfield, Illinois. | Finance |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Health Technology |
ViTToria Biotherapeutics, Inc.
 ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Health Technology |
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
Pathway To Cures
Pathway To Cures Investment ManagersFinance Pathway To Cures (Pathway To Cures) is a venture capital firm founded in 2022. The firm is headquartered in New York. | Finance |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
